Inborn Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Inborn Gene or Chromosome Alterations Pipeline Product Market Overview

The Inborn Gene or Chromosome Alterations pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.

Key Territories ·        The US

·        Europe

·        Canada

·        China

·        Australia

Key Regulatory Paths ·        510(k)

·        CE

·        TGA

·        MDL

·        NMPA

Leading Companies ·        Aarhus University

·        AC-Gen Reading Life S.L.

·        Alexion Pharmaceuticals Inc

·        Amarantus Diagnostics Inc

·        Arrayit Corp (Inactive)

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Inborn Gene or Chromosome Alterations Pipeline Market Segmentation by Territories

A few of the key territories for Inborn Gene or Chromosome Alterations pipeline products are the US, Europe, Canada, China, and Australia among others. As of December 2023, the US accounted for the highest number of pipeline products.

Inborn Gene or Chromosome Alterations Pipeline Market Analysis by Territories, 2023 (%)

Inborn Gene or Chromosome Alterations Pipeline Market Analysis by Territories, 2023 (%)

Buy the Full Report for More Territory Insights into the Inborn Gene or Chromosome Alterations Pipeline Market

Download a Free Report Sample

Inborn Gene or Chromosome Alterations Pipeline Market Segmentation by Regulatory Paths

A few of the key regulatory paths followed by the Inborn Gene or Chromosome Alterations pipeline market are 510(k), CE, TGA, MDL, and NMPA among others. As of December 2023, 510(k) was the most followed pathway for pipeline products in the market.

Inborn Gene or Chromosome Alterations Pipeline Market Analysis by Regulatory Paths, 2023 (%)

Inborn Gene or Chromosome Alterations Pipeline Market Analysis by Regulatory Paths, 2023 (%)

Buy the Full Report for More Regulatory Path Insights into the Inborn Gene or Chromosome Alterations Pipeline Market

Download a Free Report Sample

Inborn Gene or Chromosome Alterations Pipeline Market – Competitive Landscape

A few of the key companies associated with the Inborn Gene or Chromosome Alterations pipeline market are Aarhus University, AC-Gen Reading Life S.L., Alexion Pharmaceuticals Inc., Amarantus Diagnostics Inc., and Arrayit Corp (Inactive), among others.

Aarhus University (Aarhus): Aarhus is headquartered in Aarhus, Denmark. The university offers bachelor’s degree programs, master’s degree programs, and Ph.D. programs in various disciplines in arts, science and technology, health and business, and social sciences. Furthermore, Aarhus operates through various departments in the areas of aesthetics and communication, agroecology, dentistry, economics and business, and forensic medicine, among others. In addition, the university provides public sector consultancy services and has research collaborations with private companies and educational institutions.

Alexion Pharmaceuticals Inc (Alexion): It is a subsidiary of AstraZeneca Plc, headquartered in Boston, Massachusetts, the US. The company discovers, develops, and markets therapies for severe and life-threatening diseases. The company’s brands comprise Kanuma, Koselug, Soliris, StrensIQ, and Ultomiris among others. Alexion’s therapeutic areas include hematology, nephrology, neurology, metabolic, cardiology, and others. The company collaborates with various research organizations and pharmaceutical companies to develop treatments for rare and severe diseases. Alexion has a strong presence in Europe and the Middle East, North America, Latin America, and Asia Pacific.

Inborn Gene or Chromosome Alterations Pipeline Market Analysis by Companies, 2023

Inborn Gene or Chromosome Alterations Pipeline Market Analysis by Companies, 2023

Buy the Full Report for More Company Insights into the Inborn Gene or Chromosome Alterations Pipeline Market

Download a Free Report Sample

Segments Covered in the Report

Inborn Gene or Chromosome Alterations Pipeline Market Territories Outlook

  • The US
  • Europe
  • Canada
  • China
  • Australia

Inborn Gene or Chromosome Alterations Pipeline Market Regulatory Paths Outlook

  • 510(k)
  • CE
  • TGA
  • MDL
  • NMPA

Scope

This report provides:

  • An extensive coverage of the Inborn Gene or Chromosome Alterations under development.
  • An exhaustive list of major pipeline products and their details, including product descriptions, licensing and collaboration details, and other developmental activities.
  • Reviews of major players involved in the development of Inborn Gene or Chromosome Alterations and lists all their pipeline projects.
  • Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.
  • Key clinical trial data of ongoing clinical trials specific to pipeline products.
  • Recent developments in the segment/industry.

Reasons to Buy

  • Gather actionable insights from competitor information to improve R&D strategies.
  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.
  • Identify and understand important and diverse types of Inborn Gene or Chromosome Alterations under development.
  • Develop market-entry and market-expansion strategies.
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
  • Carry out In-depth analysis of the product’s current stage of development, territory, and estimated launch date.

Aarhus University
AC-Gen Reading Life S.L.
Alexion Pharmaceuticals Inc
Amarantus Diagnostics Inc
Arrayit Corp (Inactive)
Augusta University
AutoGenomics Inc
Baylor College of Medicine
Boston Children's Hospital
CareDx Inc
Children's Hospital of Philadelphia
Cincinnati Children's Hospital Medical Center
Columbia University
Columbia University Fertility Center
Daan Gene Co Ltd
Decipher GenX, Inc.
Duke University
Epinex Diagnostics Inc
Firalis SAS
Fraunhofer Institute for Cell Therapy and Immunology
Fred Hutchinson Cancer Research Center
French National Institute of Health and Medical Research
genedrive plc
Genentech USA Inc
Genomic Vision SA
genomiQa Pty Ltd
German Cancer Research Center
German Institute of Human Nutrition
Gilupi GmbH
Helmholtz Center Munich German Research Center for Health and Environment GmbH
Hummingbird Diagnostics GmbH
Interleukin Genetics Inc (Inactive)
Interpace Biosciences Inc
Johns Hopkins University
JS Genetics Inc
LS CancerDiag Ltd
Lucid Diagnostics Inc
Massachusetts Eye and Ear Infirmary
McGill University
Medical Research Council
Molecular Stethoscope Inc
Nanosphere Inc (Inactive)
National University of Singapore
Nel ASA
NewGene Ltd
Oxford Biodynamics Plc
Population Bio Inc
Precipio Inc
Predigen Inc
Quest Diagnostics Inc
Revvity Inc
Sapien Biosciences
Scipher Medicine Corp
Seattle Children's Hospital
Seegene Inc
Sophia Genetics SA
Strand Life Sciences Pvt Ltd
SUNY Upstate Medical University
Suzhou Basecare Medical Co Ltd
TBG Diagnostics Ltd
Tel Aviv University
Transplant Genomics Inc
University of California San Diego
University of Central Florida
University of Colorado
University of Illinois at Chicago
University of Michigan
University of Pennsylvania
University of Pittsburgh
Vanderbilt University
Vanessa Biotech
Virginia Commonwealth University
VitaPath Genetics, Inc.

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 8

|1.2 List of Figures 14

2 Introduction 15

2.1 Inborn Gene or Chromosome Alterations Overview 15

3 Products under Development 16

3.1 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 16

3.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Territory 17

3.3 Inborn Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 18

3.4 Inborn Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 19

3.5 Inborn Gene or Chromosome Alterations – Ongoing Clinical Trials 20

4 Inborn Gene or Chromosome Alterations – Pipeline Products under Development by Companies 21

4.1 Inborn Gene or Chromosome Alterations Companies – Pipeline Products by Stage of Development 21

4.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 24

5 Inborn Gene or Chromosome Alterations Companies and Product Overview 27

5.1 Aarhus University Company Overview 27

5.1.1 Aarhus University Pipeline Products & Ongoing Clinical Trials Overview 27

5.2 AC-Gen Reading Life S.L. Company Overview 28

5.2.1 AC-Gen Reading Life S.L. Pipeline Products & Ongoing Clinical Trials Overview 28

5.3 Alexion Pharmaceuticals Inc Company Overview 29

5.3.1 Alexion Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 29

5.4 Amarantus Diagnostics Inc Company Overview 32

5.4.1 Amarantus Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 32

5.5 Arrayit Corp (Inactive) Company Overview 33

5.5.1 Arrayit Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33

5.6 Augusta University Company Overview 34

5.6.1 Augusta University Pipeline Products & Ongoing Clinical Trials Overview 34

5.7 AutoGenomics Inc Company Overview 35

5.7.1 AutoGenomics Inc Pipeline Products & Ongoing Clinical Trials Overview 35

5.8 Baylor College of Medicine Company Overview 38

5.8.1 Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 38

5.9 Boston Children’s Hospital Company Overview 39

5.9.1 Boston Children’s Hospital Pipeline Products & Ongoing Clinical Trials Overview 39

5.10 CareDx Inc Company Overview 41

5.10.1 CareDx Inc Pipeline Products & Ongoing Clinical Trials Overview 41

5.11 Children’s Hospital of Philadelphia Company Overview 44

5.11.1 Children’s Hospital of Philadelphia Pipeline Products & Ongoing Clinical Trials Overview 44

5.12 Cincinnati Children’s Hospital Medical Center Company Overview 45

5.12.1 Cincinnati Children’s Hospital Medical Center Pipeline Products & Ongoing Clinical Trials Overview 45

5.13 Columbia University Company Overview 46

5.13.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 46

5.14 Columbia University Fertility Center Company Overview 47

5.14.1 Columbia University Fertility Center Pipeline Products & Ongoing Clinical Trials Overview 47

5.15 Daan Gene Co Ltd Company Overview 48

5.15.1 Daan Gene Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 48

5.16 Decipher GenX, Inc. Company Overview 49

5.16.1 Decipher GenX, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49

5.17 Duke University Company Overview 50

5.17.1 Duke University Pipeline Products & Ongoing Clinical Trials Overview 50

5.18 Epinex Diagnostics Inc Company Overview 51

5.18.1 Epinex Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 51

5.19 Firalis SAS Company Overview 52

5.19.1 Firalis SAS Pipeline Products & Ongoing Clinical Trials Overview 52

5.20 Fraunhofer Institute for Cell Therapy and Immunology Company Overview 53

5.20.1 Fraunhofer Institute for Cell Therapy and Immunology Pipeline Products & Ongoing Clinical Trials Overview 53

5.21 Fred Hutchinson Cancer Research Center Company Overview 54

5.21.1 Fred Hutchinson Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 54

5.22 French National Institute of Health and Medical Research Company Overview 56

5.22.1 French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 56

5.23 genedrive plc Company Overview 58

5.23.1 genedrive plc Pipeline Products & Ongoing Clinical Trials Overview 58

5.24 Genentech USA Inc Company Overview 59

5.24.1 Genentech USA Inc Pipeline Products & Ongoing Clinical Trials Overview 59

5.25 Genomic Vision SA Company Overview 60

5.25.1 Genomic Vision SA Pipeline Products & Ongoing Clinical Trials Overview 60

5.26 genomiQa Pty Ltd Company Overview 61

5.26.1 genomiQa Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 61

5.27 German Cancer Research Center Company Overview 62

5.27.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 62

5.28 German Institute of Human Nutrition Company Overview 63

5.28.1 German Institute of Human Nutrition Pipeline Products & Ongoing Clinical Trials Overview 63

5.29 Gilupi GmbH Company Overview 64

5.29.1 Gilupi GmbH Pipeline Products & Ongoing Clinical Trials Overview 64

5.30 Helmholtz Center Munich German Research Center for Health and Environment GmbH Company Overview 65

5.30.1 Helmholtz Center Munich German Research Center for Health and Environment GmbH Pipeline Products & Ongoing Clinical Trials Overview 65

5.31 Hummingbird Diagnostics GmbH Company Overview 67

5.31.1 Hummingbird Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 67

5.32 Interleukin Genetics Inc (Inactive) Company Overview 68

5.32.1 Interleukin Genetics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 68

5.33 Interpace Biosciences Inc Company Overview 70

5.33.1 Interpace Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 70

5.34 Johns Hopkins University Company Overview 72

5.34.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 72

5.35 JS Genetics Inc Company Overview 74

5.35.1 JS Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 74

5.36 LS CancerDiag Ltd Company Overview 75

5.36.1 LS CancerDiag Ltd Pipeline Products & Ongoing Clinical Trials Overview 75

5.37 Lucid Diagnostics Inc Company Overview 76

5.37.1 Lucid Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 76

5.38 Massachusetts Eye and Ear Infirmary Company Overview 80

5.38.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 80

5.39 McGill University Company Overview 82

5.39.1 McGill University Pipeline Products & Ongoing Clinical Trials Overview 82

5.40 Medical Research Council Company Overview 83

5.40.1 Medical Research Council Pipeline Products & Ongoing Clinical Trials Overview 83

5.41 Molecular Stethoscope Inc Company Overview 85

5.41.1 Molecular Stethoscope Inc Pipeline Products & Ongoing Clinical Trials Overview 85

5.42 Nanosphere Inc (Inactive) Company Overview 86

5.42.1 Nanosphere Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 86

5.43 National University of Singapore Company Overview 87

5.43.1 National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 87

5.44 Nel ASA Company Overview 88

5.44.1 Nel ASA Pipeline Products & Ongoing Clinical Trials Overview 88

5.45 NewGene Ltd Company Overview 89

5.45.1 NewGene Ltd Pipeline Products & Ongoing Clinical Trials Overview 89

5.46 Oxford Biodynamics Plc Company Overview 90

5.46.1 Oxford Biodynamics Plc Pipeline Products & Ongoing Clinical Trials Overview 90

5.47 Population Bio Inc Company Overview 98

5.47.1 Population Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 98

5.48 Precipio Inc Company Overview 106

5.48.1 Precipio Inc Pipeline Products & Ongoing Clinical Trials Overview 106

5.49 Predigen Inc Company Overview 107

5.49.1 Predigen Inc Pipeline Products & Ongoing Clinical Trials Overview 107

5.50 Quest Diagnostics Inc Company Overview 108

5.50.1 Quest Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 108

5.51 Revvity Inc Company Overview 110

5.51.1 Revvity Inc Pipeline Products & Ongoing Clinical Trials Overview 110

5.52 Sapien Biosciences Company Overview 111

5.52.1 Sapien Biosciences Pipeline Products & Ongoing Clinical Trials Overview 111

5.53 Scipher Medicine Corp Company Overview 113

5.53.1 Scipher Medicine Corp Pipeline Products & Ongoing Clinical Trials Overview 113

5.54 Seattle Children’s Hospital Company Overview 114

5.54.1 Seattle Children’s Hospital Pipeline Products & Ongoing Clinical Trials Overview 114

5.55 Seegene Inc Company Overview 115

5.55.1 Seegene Inc Pipeline Products & Ongoing Clinical Trials Overview 115

5.56 Sophia Genetics SA Company Overview 116

5.56.1 Sophia Genetics SA Pipeline Products & Ongoing Clinical Trials Overview 116

5.57 Strand Life Sciences Pvt Ltd Company Overview 117

5.57.1 Strand Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 117

5.58 SUNY Upstate Medical University Company Overview 119

5.58.1 SUNY Upstate Medical University Pipeline Products & Ongoing Clinical Trials Overview 119

5.59 Suzhou Basecare Medical Co Ltd Company Overview 120

5.59.1 Suzhou Basecare Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 120

5.60 TBG Diagnostics Ltd Company Overview 122

5.60.1 TBG Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 122

5.61 Tel Aviv University Company Overview 123

5.61.1 Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview 123

5.62 Transplant Genomics Inc Company Overview 124

5.62.1 Transplant Genomics Inc Pipeline Products & Ongoing Clinical Trials Overview 124

5.63 University of California San Diego Company Overview 125

5.63.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 125

5.64 University of Central Florida Company Overview 126

5.64.1 University of Central Florida Pipeline Products & Ongoing Clinical Trials Overview 126

5.65 University of Colorado Company Overview 128

5.65.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 128

5.66 University of Illinois at Chicago Company Overview 129

5.66.1 University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 129

5.67 University of Michigan Company Overview 130

5.67.1 University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 130

5.68 University of Pennsylvania Company Overview 132

5.68.1 University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview 132

5.69 University of Pittsburgh Company Overview 133

5.69.1 University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 133

5.70 Vanderbilt University Company Overview 135

5.70.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview 135

5.71 Vanessa Biotech Company Overview 136

5.71.1 Vanessa Biotech Pipeline Products & Ongoing Clinical Trials Overview 136

5.72 Virginia Commonwealth University Company Overview 137

5.72.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 137

5.73 VitaPath Genetics, Inc. Company Overview 138

5.73.1 VitaPath Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 138

6 Inborn Gene or Chromosome Alterations- Recent Developments 139

6.1 Dec 04, 2023: MT-RNR1 ID Kit Adopted for Routine Use in Brighton 139

6.2 Nov 28, 2023: Thermo Fisher Scientific Prices Offering Of $2.5 Bln Of Senior Notes 139

6.3 Nov 20, 2023: Labcorp and Legacy Health Finalize Comprehensive Laboratory Relationship 139

6.4 Nov 15, 2023: StageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational Update 140

6.5 Nov 10, 2023: Lucid Diagnostics introduces new EsoGuard

2.0 DNA test 141

6.6 Nov 09, 2023: Yourgene Health and Laboriad Launch Non-invasive Prenatal Testing in Morocco 141

6.7 Nov 07, 2023: SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023 Record results on growth acceleration, significant improvement in operating loss and cash burn 142

6.8 Oct 31, 2023: Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuardEsophageal Precancer Detection 142

6.9 Oct 30, 2023: Billiontoone Announces Clinical Outcomes Data for Unity Fetal Risk Screen, Demonstrating Exceptional Accuracy in General Pregnancy Population 143

6.10 Oct 27, 2023: ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023 144

6.11 Oct 26, 2023: Labcorp Announces 2023 Third Quarter Results 145

6.12 Oct 19, 2023: Invitae Appoints Dr. David Sholehvar as Chief Operating Officer 149

6.13 Oct 05, 2023: Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023 149

6.14 Sep 25, 2023: Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO 150

6.15 Sep 14, 2023: Labcorp to Present Strategy, Business and Financial Outlook at Investor Day 151

6.16 Sep 07, 2023: Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard Esophageal Precancer Detection 151

6.17 Sep 05, 2023: Yourgene Health releases MagBench DNA Extraction system in APAC and Middle East 152

6.18 Sep 05, 2023: Illumina’s Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer 152

6.19 Aug 28, 2023: Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer 153

6.20 Aug 24, 2023: Lucid Diagnostics Executes First Direct Employer Contract To Provide Esoguard Esophageal Precancer Testing As An Employee Benefit 154

6.21 Aug 21, 2023: GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine 154

6.22 Aug 17, 2023: Myriad Genetics to Host Investor Day on September 19, 2023 155

6.23 Aug 17, 2023: Illumina Expands Genomics Capabilities in India with Opening of Solutions Center 156

6.24 Aug 17, 2023: Illumina Announces Lays Off 151 San Diego workers 156

6.25 Aug 14, 2023: Invitae Announces Selection of Finance Executive Robert Dickey as Interim CFO 157

6.26 Aug 14, 2023: Thermo Fisher Scientific to Trim Staff by More Than 200 at Florida Site 157

6.27 Aug 13, 2023: Illumina Announces Departure of Chief Medical Officer and Chief Technology Officer 157

6.28 Aug 11, 2023: BillionToOne Publishes UNITY Fetal RhD and Fetal Antigen NIPT Clinical Validity Demonstrating

99.9% Accuracy 157

6.29 Aug 09, 2023: Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update 158

6.30 Aug 09, 2023: Dr. Steven Barnard Appointed Chief Technology Officer 159

6.31 Jul 31, 2023: Labcorp to Host Investor Day on September 14, 2023 160

6.32 Jul 05, 2023: Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 26, 2023 160

6.33 Jun 14, 2023: Standard BioTools to Participate in Upcoming Investor Conferences 160

6.34 Jun 05, 2023: Lucid Diagnostics launches first EsoGuard mobile test unit 161

6.35 Jun 05, 2023: StageZero Life Sciences Announces Special and Annual General Meeting Conference Call 161

6.36 Jun 02, 2023: Illumina’s Board of Directors elects two experienced Independent Directors to Board 162

6.37 May 25, 2023: Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO 163

6.38 May 18, 2023: Standard BioTools announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System 163

6.39 May 15, 2023: Standard BioTools Appoints Jeffrey Black as Chief Financial Officer 164

6.40 May 12, 2023: Grifols rolls out AlphaID At Home programme in the US 164

6.41 May 09, 2023: Invitae reports Q1 2023 financial results 165

6.42 May 09, 2023: Standard BioTools reports Q1 2023 financial results 166

6.43 May 09, 2023: Natera reports first quarter 2023 financial results 168

6.44 May 04, 2023: Cardiff Oncology reports first-quarter 2023 results and provides business update 170

6.45 May 03, 2023: Myriad Genetics reports first quarter 2023 financial results 172

6.46 Apr 26, 2023: Invitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023 173

6.47 Apr 25, 2023: Illumina reports financial results for first quarter of fiscal year 2023; announces commitment to accelerate margin growth 173

6.48 Apr 25, 2023: Standard BioTools announces conference call and webcast for first quarter 2023 financial results 175

6.49 Apr 20, 2023: QIAGEN announces expansion of supervisory board 176

6.50 Apr 18, 2023: Lucid Diagnostics reports publication of future effective foundational local coverage determination by Medicare Administrative Contractor Noridian Healthcare Solutions 176

6.51 Mar 31, 2023: StageZero Life Sciences Announces Q4 2022 and Year End Financial Results and Operational Update 177

6.52 Mar 30, 2023: Genedrive MT-RNR1 ID test receives positive final recommendation by NICE issues final guidance for use in the NHS through early value assessment programme 178

6.53 Mar 30, 2023: StageZero to Issue Q4 2022 Financial Results on Friday March 31 178

6.54 Mar 29, 2023: StageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Thursday March 30 179

6.55 Mar 17, 2023: Yourgene Health Announces Directorate Change 179

6.56 Mar 16, 2023: GeneDx presents new data at ACMG demonstrating the benefits of exome sequencing over chromosomal microarray 179

6.57 Mar 16, 2023: Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology 180

6.58 Mar 15, 2023: Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors 181

6.59 Mar 15, 2023: Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing 181

6.60 Mar 01, 2023: Devyser launches first IVDR-certified product 183

6.61 Feb 28, 2023: Invitae Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Company Updates 184

6.62 Feb 27, 2023: Daan Gene’s Prelim 2022 Net Profit Up

53.1% Y/Y 185

6.63 Feb 23, 2023: Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors 185

6.64 Feb 16, 2023: Labcorp Announces 2022 Fourth Quarter and Full-Year Results 186

6.65 Feb 14, 2023: Invitae to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023 189

6.66 Feb 14, 2023: Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook 189

6.67 Feb 09, 2023: Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE 190

6.68 Feb 07, 2023: QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups 191

6.69 Jan 31, 2023: Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results 192

6.70 Jan 20, 2023: Quest Diagnostics to Release Fourth Quarter and Full Year 2022 Financial Results on February 2, 2023 192

6.71 Jan 09, 2023: Invitae Reports Preliminary 2022 Financial Results 193

6.72 Jan 09, 2023: Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update 194

6.73 Jan 08, 2023: Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2023 195

6.74 Jan 03, 2023: Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer 197

6.75 Dec 21, 2022: Yourgene Health Announces Half-year Report 197

6.76 Dec 19, 2022: Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans 199

6.77 Dec 19, 2022: Invitae Executive Appointed to National Health Information Technology Advisory Committee 200

7 Appendix 201

7.1 Methodology 201

7.2 About GlobalData 204

7.3 Contact Us 204

7.4 Disclaimer 204

Table

Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 16

Inborn Gene or Chromosome Alterations – Pipeline Products by Territory 17

Inborn Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 18

Inborn Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 19

Inborn Gene or Chromosome Alterations – Ongoing Clinical Trials 20

Inborn Gene or Chromosome Alterations Companies – Pipeline Products by Stage of Development 21

Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 24

Aarhus University Pipeline Products & Ongoing Clinical Trials Overview 27

Cystic Fibrosis Urine Test – Product Status 27

Cystic Fibrosis Urine Test – Product Description 27

AC-Gen Reading Life S.L. Pipeline Products & Ongoing Clinical Trials Overview 28

Diagnostic Test – Hereditary Deafness – Product Status 28

Diagnostic Test – Hereditary Deafness – Product Description 28

Alexion Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 29

BeginNGS – Product Status 29

BeginNGS – Product Description 29

Alexion Pharmaceuticals Inc – Ongoing Clinical Trials Overview 30

BeginNGS – Study to Assess the BeginNGS Tool for Screening Newborns for Genetic Diseases 31

Amarantus Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Diagnostic Test – IFN-Beta Resistance – Product Status 32

Diagnostic Test – IFN-Beta Resistance – Product Description 32

Arrayit Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33

PDx Pre-Symptomatic Test – Product Status 33

PDx Pre-Symptomatic Test – Product Description 33

Augusta University Pipeline Products & Ongoing Clinical Trials Overview 34

SUMO Gene Test – Type 1 Diabetes – Product Status 34

SUMO Gene Test – Type 1 Diabetes – Product Description 34

AutoGenomics Inc Pipeline Products & Ongoing Clinical Trials Overview 35

DNA Guided Diagnostic Test – Cardiovascular Disease – Product Status 35

DNA Guided Diagnostic Test – Cardiovascular Disease – Product Description 35

DNA Guided Diagnostic Test – Diabetes – Product Status 36

DNA Guided Diagnostic Test – Diabetes – Product Description 36

DNA Guided Diagnostic Test – Obesity – Product Status 36

DNA Guided Diagnostic Test – Obesity – Product Description 37

Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 38

Diagnostic Assay – Rett Syndrome – Product Status 38

Diagnostic Assay – Rett Syndrome – Product Description 38

Boston Children’s Hospital Pipeline Products & Ongoing Clinical Trials Overview 39

Diagnostic Assay – Cystic Fibrosis – Product Status 39

Diagnostic Assay – Cystic Fibrosis – Product Description 39

Diagnostic Assay – Developmental Delay – Product Status 40

Diagnostic Assay – Developmental Delay – Product Description 40

CareDx Inc Pipeline Products & Ongoing Clinical Trials Overview 41

Diagnostic Test – Multiple Sclerosis – Product Status 41

Diagnostic Test – Multiple Sclerosis – Product Description 41

Diagnostic Test – Rheumatoid Arthritis – Product Status 42

Diagnostic Test – Rheumatoid Arthritis – Product Description 42

Diagnostic Test – Sjogren’s Syndrome – Product Status 42

Diagnostic Test – Sjogren’s Syndrome – Product Description 43

Diagnostic Test – Systemic Lupus Erythematosus – Product Status 43

Diagnostic Test – Systemic Lupus Erythematosus – Product Description 43

Children’s Hospital of Philadelphia Pipeline Products & Ongoing Clinical Trials Overview 44

Diagnostic Test – Cornelia De Lange Syndrome – Product Status 44

Diagnostic Test – Cornelia De Lange Syndrome – Product Description 44

Cincinnati Children’s Hospital Medical Center Pipeline Products & Ongoing Clinical Trials Overview 45

Diagnostic Biomarker Test – Biliary Atresia – Product Status 45

Diagnostic Biomarker Test – Biliary Atresia – Product Description 45

Columbia University Pipeline Products & Ongoing Clinical Trials Overview 46

Genetic Test – Schizophrenia – Product Status 46

Genetic Test – Schizophrenia – Product Description 46

Columbia University Fertility Center Pipeline Products & Ongoing Clinical Trials Overview 47

STORK Test – Product Status 47

STORK Test – Product Description 47

Daan Gene Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 48

Real Time PCR Kit – Beta-Mediterranean Anaemia – Product Status 48

Real Time PCR Kit – Beta-Mediterranean Anaemia – Product Description 48

Decipher GenX, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49

Diagnostic Test – Chronic Fatigue Syndrome – Product Status 49

Diagnostic Test – Chronic Fatigue Syndrome – Product Description 49

Duke University Pipeline Products & Ongoing Clinical Trials Overview 50

Diagnostic Blood Test – Respiratory Infections – Product Status 50

Diagnostic Blood Test – Respiratory Infections – Product Description 50

Epinex Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 51

Down Syndrome Screen Test – Product Status 51

Down Syndrome Screen Test – Product Description 51

Firalis SAS Pipeline Products & Ongoing Clinical Trials Overview 52

Prognostic miRNA Assay – Heart Failure – Product Status 52

Prognostic miRNA Assay – Heart Failure – Product Description 52

Fraunhofer Institute for Cell Therapy and Immunology Pipeline Products & Ongoing Clinical Trials Overview 53

Multimodal Early Screening Test – Dyslexia – Product Status 53

Multimodal Early Screening Test – Dyslexia – Product Description 53

Fred Hutchinson Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 54

FANCC Gene-Based Immuno-MRM Assay – Product Status 54

FANCC Gene-Based Immuno-MRM Assay – Product Description 54

FANCI Gene-Based Immuno-MRM Assay – Product Status 55

FANCI Gene-Based Immuno-MRM Assay – Product Description 55

French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 56

Biomarker Based Assay – Multiple Sclerosis – Product Status 56

Biomarker Based Assay – Multiple Sclerosis – Product Description 56

Genetic Diagnostic Kit – Bone Diseases – Product Status 57

Genetic Diagnostic Kit – Bone Diseases – Product Description 57

VLA-4 Based Assay – Duchenne Muscular Dystrophy – Product Status 57

VLA-4 Based Assay – Duchenne Muscular Dystrophy – Product Description 57

genedrive plc Pipeline Products & Ongoing Clinical Trials Overview 58

Genedrive MT-RNR1 Assay – Product Status 58

Genedrive MT-RNR1 Assay – Product Description 58

Genentech USA Inc Pipeline Products & Ongoing Clinical Trials Overview 59

Arbaclofen Companion Diagnostic Assay – Product Status 59

Arbaclofen Companion Diagnostic Assay – Product Description 59

Genomic Vision SA Pipeline Products & Ongoing Clinical Trials Overview 60

Spinal Muscular Atrophy Test – Product Status 60

Spinal Muscular Atrophy Test – Product Description 60

genomiQa Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 61

GulfDx – Product Status 61

GulfDx – Product Description 61

German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 62

DGKA Based Assay – Radiation-induced Fibrosis – Product Status 62

DGKA Based Assay – Radiation-induced Fibrosis – Product Description 62

German Institute of Human Nutrition Pipeline Products & Ongoing Clinical Trials Overview 63

Diagnostic Test – Obesity Associated Diabetes – Product Status 63

Diagnostic Test – Obesity Associated Diabetes – Product Description 63

Gilupi GmbH Pipeline Products & Ongoing Clinical Trials Overview 64

Diagnostic Test – Down’s Syndrome – Product Status 64

Diagnostic Test – Down’s Syndrome – Product Description 64

Helmholtz Center Munich German Research Center for Health and Environment GmbH Pipeline Products & Ongoing Clinical Trials Overview 65

2-Gene Test – Product Status 65

2-Gene Test – Product Description 65

Diagnostic Test – Pre-Diabetes – Product Status 66

Diagnostic Test – Pre-Diabetes – Product Description 66

Hummingbird Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 67

Diagnostic Test – Multiple Sclerosis – Product Status 67

Diagnostic Test – Multiple Sclerosis – Product Description 67

Interleukin Genetics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 68

Inherent Health Osteoarthritis Test – Product Status 68

Inherent Health Osteoarthritis Test – Product Description 68

Osteoporosis Risk Test – Product Status 69

Osteoporosis Risk Test – Product Description 69

Interpace Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 70

PathFinderTG – Pancreas (Supernatant) – Product Status 70

PathFinderTG – Pancreas (Supernatant) – Product Description 70

PathFinderTG – Ulcerative Colitis Supernatant – Product Status 71

PathFinderTG – Ulcerative Colitis Supernatant – Product Description 71

Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 72

Biomarker Assay – Polycythemia Vera – Product Status 72

Biomarker Assay – Polycythemia Vera – Product Description 72

Diagnostic Kit – Psychiatric Disorder – Product Status 73

Diagnostic Kit – Psychiatric Disorder – Product Description 73

JS Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 74

Dyslexia Predisposition Test – Product Status 74

Dyslexia Predisposition Test – Product Description 74

LS CancerDiag Ltd Pipeline Products & Ongoing Clinical Trials Overview 75

DiagMMR – Product Status 75

DiagMMR – Product Description 75

Lucid Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 76

EsoGuard Test – Product Status 76

EsoGuard Test – Product Description 76

Lucid Diagnostics Inc – Ongoing Clinical Trials Overview 77

EsoGuard Test – A Multicenter Case-control Study of the Efficacy of EsoGuard on Samples Collected Using EsoCheck, Versus Esophagogastroduodenoscopy, for the Diagnosis of Barrett’s Esophagus with and without Dysplasia, and for Esophageal Adenocarcinoma 78

EsoGuard Test – A Multicenter, Prospective, Open-label Registry Study to Capture Real-world Data on Esoguard Testing in at-risk Patients for the Detection of Barrett’s Esophagus or Esophageal Adenocarcinoma 78

EsoGuard Test – Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett’s Esophagus in At Risk Population (ASBE) A Randomized Controlled, Virtual Patient Trial 78

EsoGuard Test – CLUE: CLinical Utility Study of EsoGuard on Samples Collected Using EsoCheck as a Triage Test for Endoscopy to Identify Barrett’s Esophagus (BE) 79

EsoGuard Test – Detection of Barrett s Esophagus in Patients Without Gastroesophageal Reflux Disease (GERD) Symptoms 79

EsoGuard Test – Genetic and Environmental Determinants of Barrett’s Esophagus and Esophageal Adenocarcinoma 79

Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 80

GEDi Test – Inherited Eye Disorders – Product Status 80

GEDi Test – Inherited Eye Disorders – Product Description 80

GEDi Test – Strabismus – Product Status 81

GEDi Test – Strabismus – Product Description 81

McGill University Pipeline Products & Ongoing Clinical Trials Overview 82

Genetic Marker Test – Recurrent Abortions – Product Status 82

Genetic Marker Test – Recurrent Abortions – Product Description 82

Medical Research Council Pipeline Products & Ongoing Clinical Trials Overview 83

Epigenetic Test – Crohn’s Disease – Product Status 83

Epigenetic Test – Crohn’s Disease – Product Description 83

Genetic Test – Familial Hypercholesterolaemia – Product Status 84

Genetic Test – Familial Hypercholesterolaemia – Product Description 84

Molecular Stethoscope Inc Pipeline Products & Ongoing Clinical Trials Overview 85

Next-Generation cf-mRNA Test – Alzheimer’s Disease – Product Status 85

Next-Generation cf-mRNA Test – Alzheimer’s Disease – Product Description 85

Nanosphere Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 86

Verigene Processor SP System – Hemochromatosis (HFE) Nucleic Acid Test – Product Status 86

Verigene Processor SP System – Hemochromatosis (HFE) Nucleic Acid Test – Product Description 86

National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 87

Rapid Screening Assay – Fragile X Syndrome – Product Status 87

Rapid Screening Assay – Fragile X Syndrome – Product Description 87

Nel ASA Pipeline Products & Ongoing Clinical Trials Overview 88

AMYtect – Product Status 88

AMYtect – Product Description 88

NewGene Ltd Pipeline Products & Ongoing Clinical Trials Overview 89

Limb Girdle Muscular Dystrophy Test – Product Status 89

Limb Girdle Muscular Dystrophy Test – Product Description 89

Oxford Biodynamics Plc Pipeline Products & Ongoing Clinical Trials Overview 90

Companion Diagnostic Test – Amyotrophic Lateral Sclerosis – Product Status 90

Companion Diagnostic Test – Amyotrophic Lateral Sclerosis – Product Description 91

Companion Diagnostic Test – Corticobasal Degeneration – Product Status 91

Companion Diagnostic Test – Corticobasal Degeneration – Product Description 91

Companion Diagnostic Test – Dementia With Lewy Bodies – Product Status 92

Companion Diagnostic Test – Dementia With Lewy Bodies – Product Description 92

Companion Diagnostic Test – Diffuse Lewy Body Disease – Product Status 92

Companion Diagnostic Test – Diffuse Lewy Body Disease – Product Description 93

Companion Diagnostic Test – Frontotemporal Lobar Degeneration – Product Status 93

Companion Diagnostic Test – Frontotemporal Lobar Degeneration – Product Description 93

Companion Diagnostic Test – Multiple System Atrophy – Product Status 94

Companion Diagnostic Test – Multiple System Atrophy – Product Description 94

Companion Diagnostic Test – Osteoporosis – Product Status 94

Companion Diagnostic Test – Osteoporosis – Product Description 95

Companion Diagnostic Test – Parkinsonism-Dementia-Amyotrophic Lateral Sclerosis Complex – Product Status 95

Companion Diagnostic Test – Parkinsonism-Dementia-Amyotrophic Lateral Sclerosis Complex – Product Description 95

Companion Diagnostic Test – Progressive Supranuclear Palsy – Product Status 96

Companion Diagnostic Test – Progressive Supranuclear Palsy – Product Description 96

Companion Diagnostic Test – Sarcopenia – Product Status 96

Companion Diagnostic Test – Sarcopenia – Product Description 97

EpiSwitch Parkinson’s Disease Diagnostic Test – Product Status 97

EpiSwitch Parkinson’s Disease Diagnostic Test – Product Description 97

Population Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 98

Genetic Test – Amyotrophic Lateral Sclerosis – Product Status 98

Genetic Test – Amyotrophic Lateral Sclerosis – Product Description 99

Genetic Test – Bipolar Disorder – Product Status 99

Genetic Test – Bipolar Disorder – Product Description 99

Genetic Test – Diabetes Mellitus – Product Status 100

Genetic Test – Diabetes Mellitus – Product Description 100

Genetic Test – Epilepsy – Product Status 100

Genetic Test – Epilepsy – Product Description 101

Genetic Test – Multiple Sclerosis – Product Status 101

Genetic Test – Multiple Sclerosis – Product Description 101

Genetic Test – Obesity – Product Status 102

Genetic Test – Obesity – Product Description 102

Genetic Test – Progressive Multifocal Leukoencephalopathy – Product Status 102

Genetic Test – Progressive Multifocal Leukoencephalopathy – Product Description 103

Genetic Test – Pulmonary Fibrosis – Product Status 103

Genetic Test – Pulmonary Fibrosis – Product Description 103

Genetic Test – Rheumatoid Arthritis – Product Status 104

Genetic Test – Rheumatoid Arthritis – Product Description 104

Genetic Test – Schizophrenia – Product Status 104

Genetic Test – Schizophrenia – Product Description 105

Precipio Inc Pipeline Products & Ongoing Clinical Trials Overview 106

Diagnostic Test – Parkinson’s Disease – Product Status 106

Diagnostic Test – Parkinson’s Disease – Product Description 106

Predigen Inc Pipeline Products & Ongoing Clinical Trials Overview 107

Predigen Autoimmune/Inflammatory Disease Test – Product Status 107

Predigen Autoimmune/Inflammatory Disease Test – Product Description 107

Quest Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 108

Genotyping Assay – Cystic Fibrosis – Product Status 108

Genotyping Assay – Cystic Fibrosis – Product Description 108

Genotyping Assay – Fragile X Syndrome – Product Status 109

Genotyping Assay – Fragile X Syndrome – Product Description 109

Revvity Inc Pipeline Products & Ongoing Clinical Trials Overview 110

PerkinElmer Five-Plex qPCR Assay – Product Status 110

PerkinElmer Five-Plex qPCR Assay – Product Description 110

Sapien Biosciences Pipeline Products & Ongoing Clinical Trials Overview 111

Genetic Testing Panel – Autism – Product Status 111

Genetic Testing Panel – Autism – Product Description 111

Genetic Testing Panel – Diabetes – Product Status 112

Genetic Testing Panel – Diabetes – Product Description 112

Genetic Testing Panel – Perinatal Disease – Product Status 112

Genetic Testing Panel – Perinatal Disease – Product Description 112

Scipher Medicine Corp Pipeline Products & Ongoing Clinical Trials Overview 113

PrismUC – Product Status 113

PrismUC – Product Description 113

Seattle Children’s Hospital Pipeline Products & Ongoing Clinical Trials Overview 114

Diagnostic Test – Congenital Disorders – Product Status 114

Diagnostic Test – Congenital Disorders – Product Description 114

Seegene Inc Pipeline Products & Ongoing Clinical Trials Overview 115

Allplex – Thrombosis Assay – Product Status 115

Allplex – Thrombosis Assay – Product Description 115

Sophia Genetics SA Pipeline Products & Ongoing Clinical Trials Overview 116

NGS Test – Cardiac Disease – Product Status 116

NGS Test – Cardiac Disease – Product Description 116

Strand Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 117

Next-generation Sequencing Based Test – Hereditary Epilepsy – Product Status 117

Next-generation Sequencing Based Test – Hereditary Epilepsy – Product Description 117

Next-generation Sequencing Based Test – Hereditary PI – Product Status 118

Next-generation Sequencing Based Test – Hereditary PI – Product Description 118

SUNY Upstate Medical University Pipeline Products & Ongoing Clinical Trials Overview 119

Diagnostic Assay – Inflammatory Bowel Disease Risk – Product Status 119

Diagnostic Assay – Inflammatory Bowel Disease Risk – Product Description 119

Suzhou Basecare Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 120

PGT-SR Test Kit – Product Status 120

PGT-SR Test Kit – Product Description 120

WES Test Kit – Product Status 121

WES Test Kit – Product Description 121

TBG Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 122

TBG Kit – Hereditary Genetic Disease – Product Status 122

TBG Kit – Hereditary Genetic Disease – Product Description 122

Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview 123

Blood Test – Genetic Disorders – Product Status 123

Blood Test – Genetic Disorders – Product Description 123

Transplant Genomics Inc Pipeline Products & Ongoing Clinical Trials Overview 124

Diagnostic Test – Heart Transplantation – Product Status 124

Diagnostic Test – Heart Transplantation – Product Description 124

University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 125

Magnetic Nanosensor-Based miRNA Assay – Product Status 125

Magnetic Nanosensor-Based miRNA Assay – Product Description 125

University of Central Florida Pipeline Products & Ongoing Clinical Trials Overview 126

hMRS Based Genomic Assay – Mycobacterium – Product Status 126

hMRS Based Genomic Assay – Mycobacterium – Product Description 126

PCR-Free Nucleic Acid Sequences Assay – Product Status 127

PCR-Free Nucleic Acid Sequences Assay – Product Description 127

University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 128

CBS Gene Mutation Test – Product Status 128

CBS Gene Mutation Test – Product Description 128

University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 129

Diagnostic Test – Complicated Sarcoidosis – Product Status 129

Diagnostic Test – Complicated Sarcoidosis – Product Description 129

University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 130

Diagnostic Test – BRAF Negative Langerhans Cell Histiocytosis – Product Status 130

Diagnostic Test – BRAF Negative Langerhans Cell Histiocytosis – Product Description 130

Genetic Test – Neuron Disease – Product Status 131

Genetic Test – Neuron Disease – Product Description 131

University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview 132

Diagnostic Test – Upper Respiratory Tract Infection – Product Status 132

Diagnostic Test – Upper Respiratory Tract Infection – Product Description 132

University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 133

AuguryDx – Aneuploidy Assay – Product Status 133

AuguryDx – Aneuploidy Assay – Product Description 133

Biomarker Assay – Fetal Genetic Disease – Product Status 134

Biomarker Assay – Fetal Genetic Disease – Product Description 134

Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview 135

Diagnostic Assay – Premature Birth – Product Status 135

Diagnostic Assay – Premature Birth – Product Description 135

Vanessa Biotech Pipeline Products & Ongoing Clinical Trials Overview 136

Microvillus Inclusion Disease Assay – Product Status 136

Microvillus Inclusion Disease Assay – Product Description 136

Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 137

Gene Based Test – Risk of Premature Birth – Product Status 137

Gene Based Test – Risk of Premature Birth – Product Description 137

VitaPath Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 138

Diagnostic Test – Spina Bifida – Product Status 138

Diagnostic Test – Spina Bifida – Product Description 138

Glossary 203

Figures

Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 16

Inborn Gene or Chromosome Alterations – Pipeline Products by Territory 17

Inborn Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 18

Inborn Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 19

Inborn Gene or Chromosome Alterations – Ongoing Clinical Trials 20

Frequently asked questions

Inborn Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies standard reports
Currency USD
$4,000

Can be used by individual purchaser only

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Inborn Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Inborn Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies in real time.

  • Access a live Inborn Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.